Target intelligence / Profile preview

V-type proton ATPase subunit E 2 (ATP6V1E2)

Target
ATP6V1E2
Molecular classification
Enzyme, Transporter
01

Overview

V-type proton ATPase subunit E 2 (ATP6V1E2) is a component of the peripheral V1 domain of the vacuolar H^+-ATPase (V-ATPase), a multi-subunit enzyme complex involved in acidification of eukaryotic intracellular organelles such as lysosomes, endosomes, and secretory vesicles. The V1 domain is responsible for ATP hydrolysis, which powers the rotation of the central stalk and triggers proton translocation by the membrane-embedded V0 domain. The E2 subunit is predicted to enable proton-transporting ATPase activity and is necessary for maintaining the acidic environment required for protein degradation, autophagy, and cellular signaling processes. Mutations or dysfunction in V-ATPase subunits, including ATP6V1E2, are implicated in neurological and developmental disorders, lysosomal storage diseases, and renal defects. V-ATPase is considered a therapeutic target in conditions where modulation of organellar pH or autophagy is desirable, but systemic inhibition presents significant safety concerns due to its ubiquitous essential functions.

Other names
VATE2ATP6E1ATP6EL2ATP6V1EL2V-ATPase subunit E 2MGC9341VMA4Vacuolar proton pump subunit E 2Testis secretory sperm-binding protein Li 235PVacuolar-type proton-translocating ATPase subunit E1Lysosomal 31kDa V1 subunit E2V-ATPase subunit E2
02

Mechanism of action

Inhibition of proton translocation by blocking V-ATPase, leading to elevated lysosomal pH and suppression of autophagy; Inhibition of ATP-driven proton transport

03

Biological functions

Proton transmembrane transportIntracellular compartment acidificationRegulation of macroautophagyATP hydrolysispH regulation
04

Disease associations

Arthrogryposis, renal dysfunction, and cholestasis 1Syndromic X-linked intellectual disability, Hedera typeNeurodevelopmental disorders (related to V-ATPase dysfunction, especially in other subunits)Other lysosomal (acidification-associated) disorders
05

Safety considerations

Global inhibition or dysfunction leads to disruption of lysosomal acidification, affecting protein degradation, autophagy, and multiple cellular processes—high risk of toxicityEmbryonic lethality observed in knockout animal models for some V-ATPase subunitsNeuronal cell death and multi-organ dysfunction when V-ATPase is disrupted
06

Interacting drugs

Bafilomycin A1 (research inhibitor of V-ATPases, not approved therapeutically)

Beyond the preview

Go deeper on V-type proton ATPase subunit E 2 (ATP6V1E2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on V-type proton ATPase subunit E 2 (ATP6V1E2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call